Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2015
Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 TrialsHeinz Haverkamp, Boris Böll, Dennis A Eichenauer, et al.
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|March 18, 2024
[Handoffs in the intensive care unit]Eyleen Reifarth, Jan-Hendrik Naendrup, Jorge Garcia Borrega, et al.
Deutsche Medizinische Wochenschrift (1946)|July 13, 2021
[Update 2021: COVID-19 from the perspective of intensive care]Stephanie-Susanne Stecher, Hans Joachim Stemmler, Dennis A Eichenauer, et al.
Blood|August 2, 2018
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Lena Schröder, et al.
Annals of Hematology|August 17, 2022
Scheduled removal of central venous catheters (CVC) to prevent CVC-related bloodstream infections in patients with hematological disease or autologous stem cell transplantation: a registry-based randomized simulation-studyJens Panse, Daniela Tölle, Eva Fiegle, et al.
Infection|March 27, 2020
Clostridioides difficile infections in the intensive care unit: a monocentric cohort studyRebeca Cruz Aguilar, Jon Salmanton-García, Jonathan Carney, et al.
European Journal of Neurology|August 16, 2023
Botulism after intragastric botulinum toxin injections for weight reductionChristina Hennen, Seda Demir, Haidar Salimi Dafsari, et al.
Infection|April 4, 2023
Impact of the insertion site of central venous catheters on central venous catheter-related bloodstream infections in patients with cancer: results from a large prospective registryMarcus Hentrich, Boris Böll, Daniel Teschner, et al.
Blood|August 11, 2011
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study GroupDennis A Eichenauer, Michael Fuchs, Annette Pluetschow, et al.
Der Internist|May 25, 2021
[Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects]Jorge Garcia Borrega, Katrin Heindel, Yasemin Göreci, et al.
Pageof 10